DBV Technologies (NASDAQ:DBVT) Reaches New 1-Year Low – Should You Sell?

Posted by Brian Himes on Oct 10th, 2026

Shares of DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) hit a new 52-week low on Thursday. The stock traded as low as $9.64 and last traded at $9.77, with a volume of 535,276 shares changing hands. The stock had previously closed at $9.98.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DBVT. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of DBV Technologies in a research report on Thursday, September 10th. Citizens Jmp raised their target price on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 30th. Weiss Ratings downgraded DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Citigroup reiterated a “market outperform” rating on shares of DBV Technologies in a report on Wednesday, September 30th. Finally, Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

Get Our Latest Report on DBV Technologies

DBV Technologies Stock Performance

The company has a 50 day moving average of $12.87 and a 200 day moving average of $16.19. The stock has a market capitalization of $616.22 million, a price-to-earnings ratio of -2.79 and a beta of -1.04.

Institutional Trading of DBV Technologies

A number of large investors have recently bought and sold shares of the business. Royal Bank of Canada grew its stake in shares of DBV Technologies by 167.1% during the 1st quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after purchasing an additional 2,928 shares during the period. Personal CFO Solutions LLC acquired a new position in DBV Technologies during the first quarter worth about $264,000. Cetera Investment Advisers raised its position in DBV Technologies by 93.4% during the first quarter. Cetera Investment Advisers now owns 25,358 shares of the company’s stock worth $530,000 after acquiring an additional 12,243 shares during the last quarter. AdvisorShares Investments LLC acquired a new stake in shares of DBV Technologies during the first quarter valued at $1,052,000. Finally, Polymer Capital Management HK LTD purchased a new stake in DBV Technologies in the 4th quarter worth approximately $1,236,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s technology is designed to deliver therapeutic proteins through the skin without needles, with the goal of gradually modifying the immune system’s response to specific allergens.

DBV Technologies’ principal product candidate is Viaskin Peanut, an investigational epicutaneous immunotherapy designed to expose patients to small amounts of peanut protein through a wearable patch.